Keenova
Keenova Therapeutics is a specialty pharmaceutical company formed in November 2025 from the $6.7 billion merger of Mallinckrodt and Endo, focused on rare and underserved conditions across Immunology, Urology, Orthopedics, Critical Care, and Pediatric Endocrinology, with a planned NYSE IPO in H2 2026.
- Company typePrivate
- Founded2025
- HeadquartersBlanchardstown, Ireland
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Keenova does
Keenova Therapeutics is a specialty pharmaceutical company formed in November 2025 through the $6.7 billion merger of Mallinckrodt and Endo, creating a combined entity focused on rare and underserved conditions. Headquartered in Blanchardstown, Dublin, Ireland, with significant U.S. operations in Malvern, Pennsylvania, Keenova operates across five therapeutic areas: Immunology, Urology & Men's Health, Orthopedics, Critical Care, and Pediatric Endocrinology. The company employs between 1,001 and 5,000 people and is currently private, with plans to list on the NYSE in the second half of 2026.
The product portfolio centers on established specialty brands: XIAFLEX (collagenase clostridium histolyticum) for Dupuytren's contracture and Peyronie's disease, Acthar Gel (repository corticotropin injection) for inflammatory and autoimmune conditions, TERLIVAZ (terlipressin) for hepatorenal syndrome-acute kidney injury, and Aveed (testosterone undecanoate) for hypogonadism. XIAFLEX is the flagship growth asset, with 100,000 men prescribed it for Peyronie's as of January 2026, and a Phase 3 trial in plantar fibromatosis is expected to read out in mid-2026, representing a potential third indication expansion. The combined entity has been shaped by the prior bankruptcies of both predecessor companies related to opioid litigation, leaving a more focused, rare-disease-oriented portfolio than either constituent company historically operated.
Keenova operates a branded specialty pharmaceutical business model: revenue is generated through drug pricing and reimbursement via specialty pharmacies, hospital systems, and physician office channels tailored to each therapeutic area. The company reported Q4 2025 revenue of $543 million from continuing operations (+104% year-over-year, largely driven by merger consolidation) and has guided to $1.94–2.00 billion for full-year 2026, with Adjusted EBITDA guidance of $730–760 million (implied ~37–38% EBITDA margin). Direct-to-consumer marketing has been deployed selectively, including the "Don't Be a Viking" campaign launched in May 2026 to address underdiagnosis of Peyronie's disease, signaling willingness to fund consumer demand generation for rare indications. AI capabilities are limited to operational use in clinical trial execution through sandbox site rehearsals with technology partners YPrime and Veeva.
Keenova firmographics
Firmographics- Name
- Keenova
- Legal name
- Keenova Therapeutics plc
- Website
- https://keenova.com
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Keenova Therapeutics is a specialty pharmaceutical company formed in November 2025 from the $6.7 billion merger of Mallinckrodt and Endo, focused on rare and underserved conditions across Immunology, Urology, Orthopedics, Critical Care, and Pediatric Endocrinology, with a planned NYSE IPO in H2 2026.
- Ownership category
- akta.pro rank
Keenova industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industries
- Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Rare Cardiovascular & Vascular Disorder Therapies (HLAIAIAH), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Nephrology & Urology Pharmaceuticals (HLAIAAAM)
Keywords
Where Keenova is headquartered
LocationHeadquarters
- HQ city
- Blanchardstown
- HQ country
- Ireland
- HQ region
- Europe
Offices7 records
Markets served
Keenova business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Pharmaceutical Product Sales: Keenova generates revenue through the sale of branded pharmaceutical products including Acthar Gel, XIAFLEX, TERLIVAZ, and other specialty therapeutics. Revenue is derived from continuing operations across multiple therapeutic areas.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Multi-year contract | Acthar Gel 5 mL multi-dose vial |
| Unit Pricing | Multi-year contract | Acthar Gel SelfJect 80 USP Units/mL (4 count) |
| Unit Pricing | Multi-year contract | Acthar Gel SelfJect 40 USP Units/0.5mL (4 count) |
| Unit Pricing | Multi-year contract | Xiaflex 1 x1 single-use 0.9mg Vial with Sterile Diluent |
| Unit Pricing | Multi-year contract | Aveed 750 mg/3 mL single-use injection |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels7 records
Keenova product offering
Product offeringCore offering
Keenova Therapeutics plc is a specialty therapeutics company that develops, manufactures, and commercializes branded prescription drugs in immunology, urology/men's health, orthopedics, critical care, and pediatric endocrinology. Its marketed portfolio includes XIAFLEX, Acthar Gel, TERLIVAZ, and Aveed, produced across five U.S. manufacturing facilities and distributed primarily through specialty pharma channels.
Product overview
Keenova is a specialty therapeutics company focused on rare and unaddressed medical conditions. The company commercializes branded pharmaceuticals across five therapeutic areas: Immunology (Acthar Gel), Urology and Men's Health (XIAFLEX for Peyronie's disease, testosterone products), Orthopedics (XIAFLEX for Dupuytren's contracture), Critical Care (TERLIVAZ for hepatorenal syndrome), and Pediatric Endocrinology (central precocious puberty). The product portfolio includes XIAFLEX (collagenase clostridium histolyticum) for Dupuytren's contracture and Peyronie's disease; Acthar Gel in multiple formulations (5 mL multi-dose vial, 80 USP Units/mL and 40 USP Units/0.5mL single-dose pre-filled SelfJect injectors) for immunology and rare conditions; TERLIVAZ (terlipressin), the first and only FDA-approved therapy for hepatorenal syndrome-acute kidney injury; and Aveed (testosterone undecanoate) 750 mg/3 mL injection. Keenova was formed from the November 2025 merger of Mallinckrodt and Endo ($6.7 billion), with 2024 pro forma combined revenue of $1.7 billion.
Differentiator
Problem solved
Functional benefit
Products and services
- XIAFLEX XIAFLEX is a branded injectable specialty therapeutic indicated for use in urology/men's health, used by specialist prescribers (notably urologists) for the treatment of eligible adult patients with conditions within its labeled indications.
- Acthar Gel Acthar Gel is a branded injectable specialty therapeutic used across immunology and related specialty indications, prescribed by specialist physicians such as rheumatologists and neurologists for eligible patients within its labeled uses.
- TERLIVAZ TERLIVAZ is a branded specialty therapeutic indicated for use in critical care settings, administered by intensivists and hospital-based clinicians for eligible critically ill patients within its labeled indication.
- Aveed Aveed is a branded injectable specialty therapeutic in the men's health/endocrinology area, prescribed by specialist physicians (such as endocrinologists and urologists) for eligible adult patients within its labeled indication.
Quantifiable outcome
- 100,000 men prescribed XIAFLEX for Peyronie's disease as of January 2026
- +2 more outcomes
Companies that use Keenova
Customer profileNamed customers1 record
Segments5 records
Ideal customer profiles1 record
Keenova technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature3 records
Keenova partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered minor.
- Questex's Fierce Life SciencesminorKeenova is participating in the 2nd annual Partnerships with Sites Summit organized by Questex's Fierce Life Sciences, convening clinical trial sites, sponsors, and CROs to address patient enrollment challenges.
- Eli LillyminorPharmaceutical company participating in the Partnerships with Sites Summit to address clinical trial patient enrollment challenges.
- BiogenminorBiotechnology company participating in the Partnerships with Sites Summit.
- Boehringer IngelheimminorPharmaceutical company participating in the Partnerships with Sites Summit.
- AstraZenecaminorPharmaceutical company participating in the Partnerships with Sites Summit.
- NovartisminorPharmaceutical company participating in the Partnerships with Sites Summit.
- Bristol Myers Squibb (BMS)minorPharmaceutical company participating in the Partnerships with Sites Summit.
- TakedaminorPharmaceutical company participating in the Partnerships with Sites Summit.
- MerckminorPharmaceutical company participating in the Partnerships with Sites Summit.
- TevaminorPharmaceutical company participating in the Partnerships with Sites Summit.
- SanofiminorPharmaceutical company participating in the Partnerships with Sites Summit.
Scale indicators9 records
Recent moves8 records
Expansion highlights5 records
Keenova competitors and assessment
Company assessmentMarket position
Strengths4 records
Weaknesses2 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Keenova social profiles
Digital presenceKeenova financial estimates
Financial estimateRevenue estimate
Valuation estimate
Keenova leadership team
Management profileNumber of profiles
Profiles1 record
Keenova funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Keenova M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Keenova
What does Keenova do?
Keenova Therapeutics plc is a specialty therapeutics company that develops, manufactures, and commercializes branded prescription drugs in immunology, urology/men's health, orthopedics, critical care, and pediatric endocrinology. Its marketed portfolio includes XIAFLEX, Acthar Gel, TERLIVAZ, and Aveed, produced across five U.S. manufacturing facilities and distributed primarily through specialty pharma channels.
Is Keenova a public or private company?
Keenova is a private company. It is classified as unknown and is currently operating.
When was Keenova founded?
Keenova was founded in 2025. It employs 501 to 1,000 people.
Where is Keenova based?
Keenova is headquartered in Blanchardstown, Ireland, in the Europe region.
How does Keenova make money?
One revenue line is on record: pharmaceutical Product Sales.
Does Keenova have an API?
No public API is recorded for Keenova.
What industry is Keenova in?
Keenova's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIACAH, Nephrology & Urology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.